Please ensure Javascript is enabled for purposes of website accessibility

Should You Buy Vir Biotechnology Stock on the Dip?

By Zhiyuan Sun - Sep 15, 2020 at 6:30AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors bid its shares way up this year, but the market just slashed their value.

One of the biggest winners among coronavirus stocks in 2020 has been Vir Biotechnology (VIR -4.12%). The company's shares have more than doubled in the span of one year, turning a $10,000 investment from last September into about $22,700 today. That substantially outperformed the S&P 500, which gained 15% over the same period.

But sometimes, the higher you climb, the harder you fall. Recent controversy surrounding the company's progress with its COVID-19 programs caused the stock to fall more than 40% from its peak in late August. Should investors expect this company and its stock to rebound? Let's take a look at whether buying Vir on the dip is a golden opportunity or whether the company's drug pipeline spells trouble for its future.

Snapshot of stethoscope, coronavirus sticker, pills, and needle.

Image Source: Getty Images.

A slow-moving COVID-19 pipeline

Vir has two antibody treatments and a small interfering RNA (siRNA) treatment against COVID-19 in its pipeline. siRNA therapeutic candidates are based on tiny double-stranded RNA sequences coded to destroy genetic material responsible for a virus' protein synthesis, rendering it unable to replicate. The RNA treatment is undergoing preclinical studies, the results from which are expected by the end of the year. Meanwhile, one of the company's antibodies, VIR-7832, will enter phase 2 clinical trials in the fourth quarter, while the other, VIR-7831, is in phase 2/3 clinical trials. The latter candidate could made available first under an early access program like an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) in the early months of 2021, if trial results are positive.

Vir has partnered with GlaxoSmithKline (GSK 0.89%) to develop its COVID-19 programs. The company is responsible for research and development (R&D) costs while GlaxoSmithKline is handling commercialization costs. Under the agreement, 72.5% of costs and profits go to Vir while the remaining 27.5% are GlaxoSmithKline's.

Without a doubt, Vir's pipeline has potential. However, there are already coronavirus treatments on the market, including Gilead Sciences' (GILD 0.18%) antiviral, remdesivir, and the generic steroid, dexamethasone. What's more, large-cap biotechs such as Moderna (MRNA -4.99%) and Pfizer (PFE 0.22%) are already far along in their efforts to develop coronavirus vaccines. In fact, a vaccine could be available as soon as October. While there are no guarantees that any one of the vaccine candidates in particular will prove effective against COVID-19, it is likely that by 2022, the need for coronavirus treatments will have significantly diminished as people around the world are (hopefully) inoculated.

A hepatitis B candidate with company

The company's hepatitis B pipeline is facing similar problems. Even though its treatment candidates for the disease are well into phase 2 trials, the question of their commercial feasibility is a key concern. There are already a number of effective hepatitis B vaccines available worldwide, meaning that the need for a treatment is limited to those who don't get immunized (or those whose immunizations are ineffective) and subsequently contract the virus. While 257 million people are currently living with hepatitis B, many are in developing nations and may not have the purchasing power to afford a pricey treatment course. 

If that wasn't enough, Arrowhead Pharmaceuticals (ARWR -1.41%) and Johnson & Johnson (JNJ 0.89%) are also on their way to developing a treatment for hepatitis B. Clinical data for their candidate has looked solid. Whatever comes out of Vir's pipeline would have to compete with both existing standard-of-care treatments such as Entecavir and Tenofovir and new ones from other biotechs. This would significantly affect the company's pricing power in the event of its drug's approval.

Buying the dip isn't always the smart move

Vir only brought in $67 million in combined licensing plus collaboration revenues in the past quarter. But currently, it has about $552.4 million in cash and investments, is operating at a net loss of $31.2 million per quarter, and has a $4.05 billion market cap. So in terms of its ability to keep moving forward with research and development, Vir's financial position is fair.

However, I don't think its shaky pipeline can justify its stock price, even after a recent decline. The market opportunities for hepatitis B and COVID-19 treatment candidates are too unstable and full of heavyweight pharma competitors. Buying Vir Biotechnology now could be like catching a falling knife. Investors looking at coronavirus stocks may wish to consider other opportunities

Zhiyuan Sun owns shares of Arrowhead Pharmaceuticals. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Vir Biotechnology, Inc. Stock Quote
Vir Biotechnology, Inc.
VIR
$26.75 (-4.12%) $-1.15
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$49.86 (0.22%) $0.11
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$167.57 (0.89%) $1.48
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$66.33 (0.18%) $0.12
GSK Stock Quote
GSK
GSK
$35.26 (0.89%) $0.31
Arrowhead Pharmaceuticals, Inc. Stock Quote
Arrowhead Pharmaceuticals, Inc.
ARWR
$47.63 (-1.41%) $0.68
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$167.96 (-4.99%) $-8.82

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
403%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.